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INTRODUCTION
TPA
•Tissue plasminogen activator(tPA) is a serine protease involved in
the breakdown of the blood clots.
•Tenecteplase (TNK) is a recombinant variant of the tPA, which has
higher fibrin specificity and greater resistance to inactivation.
Figure 1. Crystal
structure of tPA
Figure 2. The blood
clotting cascade
where acts tPA
OBJECTIVE OF THE PROJECT
PRIMITIVE PROBLEM: Design a process for producing tPA in
China.
SPECIFIC PROBLEM: Produce 30 kg / year of TNK, which cover
about 5% of cases of cerebrovascular disease China.
MATERIALS AND METHODS
SuperPro Designer is a simulator that facilitates the planning,
modeling, evaluation and optimization of processes. Once the
search for information, knowing the equipment, the operations
that are carried out in each one and the inputs and outputs, we
can make balances and economical calculations.
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•Approved by Food and Drug Adminsitration (FDA) in the year
2000.
•It is used for treating cerebrovascular diseases caused by blood
clots.
DESCRIPTION OF THE SOLUTION
Blocks 
diagram
Flow 
diagram
P&I Diagram Lay-out
•MAIN CHARACTERISTICS OF THE PROCESS
•Continuous operation, operating for three months. Perfusion.
•CHO cell line DUKxB11. Immobilized cells.
•Production of 30 kg / year of TNK.
Autodesk AutoCAD is a computer-aided design software for
drawing in two and three dimensions. Having defined the flow
will allow us design the layout.
PROCESS SUMMARY
The process consists of three parts clearly separated:
Upstream (Blue). Preparation of raw materials and inoculum. Duration: 10 days.
Reaction (Red). In continuous with immobilized cells. Medium flow: 500 L/h.
Downstream (Black). Separation and purification of the product of interest.
The technical characteristics of the process are specifically addressed in the second poster.
ECONOMICAL SUMMARY
The comprehensive economic analysis is the third poster.
Capital Investment Charged to This Project 1 039 226 000 $
Payback Time 2.58 years
Unit Production Cost 1 461 403.06 $/kg
Unit Production Revenue 25 000 000 $/kg
ital Investment Charged to This Project 039 millions $
ack Time  years
it roduction Cost .  millions $/kg
it roduction Revenue  millions $/kg
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PRESENTATION OF THE PLANT
We have an area of 50.000 m2 in China
Different areas depending on if required
sterility:
•Offices (Red)
•Production area (green)
•All entries in this area should be controlled.
Everything in and out of there must have been
previously sterilized, maintaining these
conditions at all times.
•Truck’s circuit (blue)
•We thought it appropriate to make a separate
entry and exit of trucks to ease traffic and
minimize maneuvering in and out of the docks.
•Parking for employees and visitors.
The entire facility is fenced and all inputs are
guarded.
1. Checkpoints
1. Input from outside
and dressing rooms
2. Laboratory
3. Toilets
4. Production area
5. Store of the raw
materials
6. Store of the final
product
7. Liquid storage
tanks
1. Toilets
2. Offices
3. Auditorium
4. Offices and
meeting rooms
5. Cafeteria
6. Input from outside
7. Input from the
parking
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We have built a plausible flux diagram, and a possible
lay-out of a plant to produce TNK. Although it is an
approach, it seems to be an economically viable
project.
